FRX vs. SLS, TEV, ABT, NOT, PYR, NVO, DNA, VBV, CUS, and AIM
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Solaris Resources (SLS), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), and Aimia (AIM). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs.
Solaris Resources (TSE:SLS) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Solaris Resources presently has a consensus price target of C$13.50, indicating a potential upside of 162.65%. Given Solaris Resources' higher possible upside, equities research analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.
25.1% of Solaris Resources shares are owned by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. 40.6% of Solaris Resources shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Solaris Resources' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.
Solaris Resources has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Solaris Resources is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals received 90 more outperform votes than Solaris Resources when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 48.28% of users gave Solaris Resources an outperform vote.
Fennec Pharmaceuticals has a net margin of 5.59% compared to Solaris Resources' net margin of 0.00%. Solaris Resources' return on equity of -148.58% beat Fennec Pharmaceuticals' return on equity.
Summary
Fennec Pharmaceuticals beats Solaris Resources on 11 of the 16 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 1/18/2025 by MarketBeat.com Staff
Free FRX Stock Alerts